Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

230 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Weekly taxanes in metastatic breast cancer (review).
Zimatore M, Danova M, Vassallo E, Porta C, Macaluso MC, Schittone L, Riccardi A, Palmeri S. Zimatore M, et al. Among authors: danova m. Oncol Rep. 2002 Sep-Oct;9(5):1047-52. Oncol Rep. 2002. PMID: 12168071 Review.
Paclitaxel in anthracycline-treated breast cancer patients.
Pugliese P, Brugnatelli S, Giordano M, Danova M, De Monte A, Richetti A, Fava S, Rinaldi E, Fregoni V, Epifani C, Riccardi A. Pugliese P, et al. Among authors: danova m. Oncol Rep. 1998 Jul-Aug;5(4):915-8. doi: 10.3892/or.5.4.915. Oncol Rep. 1998. PMID: 9625845 Clinical Trial.
Myeloprotective effect of early primary granulocyte-colony stimulating factor during six courses of intensified 5-fluorouracil, epirubicin and cyclophosphamide (120FEC) chemotherapy for advanced breast cancer. Cooperative Group of Study and Treatment of Breast Cancer.
Riccardi A, Brugnatelli S, Giordano M, Danova M, Pugliese P, Tinelli C, Klersy C, Richetti A, Fava S, Nastasi G, Rinaldi E, Fregoni V, De Monte A, Trotti G, Bovio A, Ascari E. Riccardi A, et al. Among authors: danova m. Tumori. 1998 Sep-Oct;84(5):540-6. doi: 10.1177/030089169808400506. Tumori. 1998. PMID: 9862513 Clinical Trial.
Doubling of the epirubicin dosage within the 5-fluorouracil, epirubicin and cyclophosphamide regimen: a prospective, randomized, multicentric study on antitumor effect and quality of life in advanced breast cancer.
Riccardi A, Tinelli C, Brugnatelli S, Pugliese P, Giardina V, Giordano M, Danova M, Richetti A, Fava S, Rinaldi E, Fregoni V, Trotti G, Poli A. Riccardi A, et al. Among authors: danova m. Int J Oncol. 2000 Apr;16(4):769-76. doi: 10.3892/ijo.16.4.769. Int J Oncol. 2000. PMID: 10717247 Clinical Trial.
230 results